Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Introducing human papillomavirus vaccines into the health system in South Africa.

Botha MH, Dochez C.

Vaccine. 2012 Sep 7;30 Suppl 3:C28-34. doi: 10.1016/j.vaccine.2012.03.032. Review.

PMID:
22939017
2.

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.

Schwarz TF.

Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18. Review.

PMID:
20024678
3.

Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

Poljak M.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Review.

4.

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

Dunne EF, Datta SD, E Markowitz L.

Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763. Review.

5.

[Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].

Bégué P, Henrion R, Blanc B, Girard M, Sancho-Garnier H.

Bull Acad Natl Med. 2007 Dec;191(9):1805-16; discussion 1816-7. French.

PMID:
18663976
6.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
7.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

8.

Human papillomavirus, cervical cancer, and the vaccines.

Tovar JM, Bazaldua OV, Vargas L, Reile E.

Postgrad Med. 2008 Jul;120(2):79-84. doi: 10.3810/pgm.2008.07.1794. Review.

PMID:
18654072
9.

Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

Adams M, Jasani B, Fiander A.

Vaccine. 2007 Apr 20;25(16):3007-13. Epub 2007 Jan 18. Review.

PMID:
17292517
10.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
11.

Preparing for HPV vaccination in South Africa: key challenges and opinions.

Harries J, Moodley J, Barone MA, Mall S, Sinanovic E.

Vaccine. 2009 Jan 1;27(1):38-44. doi: 10.1016/j.vaccine.2008.10.033. Epub 2008 Oct 31.

PMID:
18977271
12.

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.

Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG.

Vaccine. 2007 Aug 14;25(33):6245-56. Epub 2007 Jun 21.

PMID:
17630049
13.

Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.

Monsonego J, Cortes J, Greppe C, Hampl M, Joura E, Singer A.

Vaccine. 2010 Nov 29;28(51):8065-72. doi: 10.1016/j.vaccine.2010.10.017. Epub 2010 Nov 16. Review.

PMID:
20971114
14.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
15.
16.

Human papillomavirus vaccines: current issues & future.

Kawana K, Yasugi T, Taketani Y.

Indian J Med Res. 2009 Sep;130(3):341-7. Review.

PMID:
19901444
17.

Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.

Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH.

Vaccine. 2008 Aug 19;26 Suppl 12:M60-70. doi: 10.1016/j.vaccine.2008.05.042.

PMID:
18945415
18.

A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.

Goldstone SE, Vuocolo S.

Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20. Review.

PMID:
22551023
19.

Human papillomavirus (HPV) vaccines: a Canadian update.

Foerster V, Murtagh J.

Issues Emerg Health Technol. 2007 Dec;(109):1-8.

PMID:
18062141
20.

Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.

Broomall EM, Reynolds SM, Jacobson RM.

Postgrad Med. 2010 Mar;122(2):121-9. doi: 10.3810/pgm.2010.03.2129. Review.

PMID:
20203463

Supplemental Content

Support Center